Balance Sheet
Accumulated ExpensesAssetsCash & Current InvestmentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Cresco Labs (CRLBF) Other Non-Current Liabilities (2019 - 2025)

Historic Other Non-Current Liabilities for Cresco Labs (CRLBF) over the last 7 years, with Q3 2025 value amounting to $165.2 million.

  • Cresco Labs' Other Non-Current Liabilities rose 766.9% to $165.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $165.2 million, marking a year-over-year increase of 766.9%. This contributed to the annual value of $122.5 million for FY2024, which is 79301.44% up from last year.
  • Per Cresco Labs' latest filing, its Other Non-Current Liabilities stood at $165.2 million for Q3 2025, which was up 766.9% from $150.5 million recorded in Q2 2025.
  • Over the past 5 years, Cresco Labs' Other Non-Current Liabilities peaked at $165.2 million during Q3 2025, and registered a low of $7.0 million during Q1 2022.
  • For the 5-year period, Cresco Labs' Other Non-Current Liabilities averaged around $72.5 million, with its median value being $21.8 million (2024).
  • As far as peak fluctuations go, Cresco Labs' Other Non-Current Liabilities plummeted by 1813.72% in 2022, and later soared by 79301.44% in 2024.
  • Cresco Labs' Other Non-Current Liabilities (Quarter) stood at $7.0 million in 2021, then soared by 83.23% to $12.9 million in 2022, then grew by 6.3% to $13.7 million in 2023, then soared by 793.01% to $122.5 million in 2024, then surged by 34.86% to $165.2 million in 2025.
  • Its Other Non-Current Liabilities stands at $165.2 million for Q3 2025, versus $150.5 million for Q2 2025 and $135.8 million for Q1 2025.